TITLE

Two Regimens of Azithromycin Prophylaxis against Community-Acquired Respiratory and Skin/Soft-Tissue Infections among Military Trainees

AUTHOR(S)
Guchev, Igor A.; Gray, Gregory C.; Klochkov, Oleg I.
PUB. DATE
April 2004
SOURCE
Clinical Infectious Diseases;4/15/2004, Vol. 38 Issue 8, p1095
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Epidemics of community-acquired pneumonia (CAP) are a frequent cause of morbidity among Russian military trainees. We evaluated azithromycin prophylaxis against CAP. In 2001-2002, incoming military trainees were randomized to 1 of 3 trial arms by training group: azithromycin, 500 mg per week for 8 weeks (R1); azithromycin, 1500 mg once at enrollment (R2); or no therapy (R3). During the 22 weeks of training, CAP was diagnosed in 20.2% of 678 subjects in the R3 group, 8.6% of 508 subjects in the R1 group, and 10.3% of 507 subjects in the R2 group. Throat carriage cultures revealed that the proportion of Streptococcus pneumoniae isolates with resistance to macrolides correspondingly increased during the study, from 0% (all) to 40% (R1) and 22.6% (R2) by week 20. Azithromycin prophylaxis is effective against CAP in a healthy population of young men at transient high risk of disease; however, azithromycin use must be tempered with the possible concomitant risk of selection for resistant endemic pathogens.
ACCESSION #
13015112

 

Related Articles

  • Is Azithromycin the First-Choice Macrolide for Treatment of Community-Acquired Pneumonia? Sánchez, Francesca // Clinical Infectious Diseases;7/1/2004, Vol. 39 Issue 1, p145 

    This article presents response of the author to an article about the treatment of community-acquired pneumonia (CAP) with two macrolides, clarithromycin and azithromycin. The severity of CAP in patients who have received a diagnosis of CAP in the author's hospital has been scored using the...

  • Consider adding this drug to fight COPD that's severe. Hobbs, Keia; Brown, Dionna; Mounsey, Anne // Journal of Family Practice;Jul2012, Vol. 61 Issue 7, p414 

    Daily use of azithromycin, in conjunction with the usual COPD regimen, has been found to reduce acute exacerbations in patients with moderate to severe disease.

  • Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Wolter, J.; Seeney, S.; Bell, S.; Bowler, S.; Masel, P.; McCormack, J. // Thorax;Mar2002, Vol. 57 Issue 3, p212 

    Background: Relentless chronic pulmonary inflammation is the major contributor to morbidity and mortality in patients with cystic fibrosis (CF). While immunomodulating therapies such as prednisolone and ibuprofen may be beneficial, their use is limited by side effects. Macrolides have...

  • Azithromycin Extended Release: A Review of its Use in the Treatment of Acute Bacterial Sinusitis and Community-Acquired Pneumonia in the US. Swainston, Tracy; Kean, Susan J. // Drugs;2007, Vol. 67 Issue 5, p773 

    Azithromycin is a macrolide antibacterial agent. The novel microspheres oral extended-release formulation (Zmaxâ„¢) is the first antibacterial drug approved in the US for administration as a single dose in adult patients with mild to moderate acute bacterial sinusitis (ABS) or...

  • Macrolides in cystic fibrosis. Bell, SC; Senini, SL; McCormack, JG // Chronic Respiratory Disease;2005, Vol. 2 Issue 2, p85 

    Macrolide antibiotics have been licensed since the 1950s and have an important role in the treatment of a diverse range of infectious diseases. Macrolide antibiotics have antibacterial activity against grampositive bacteria, some gram-negative bacteria and intracellular pathogens. The spectrum...

  • Daily Azithromycin May Prevent COPD Exacerbations. Friswell, Andrea C. // Pulmonary Reviews;Oct2011, Vol. 16 Issue 10, p19 

    The article discusses a study published in the August 25, 2011 issue of "New England Journal of Medicine" which found a reduction in the number of acute exacerbations in patients of chronic obstructive pulmonary disease who take prophylactic azithromycin.

  • Complete Elimination Is a Difficult Goal for Trachoma Programs in Severely Affected Communities. Gill, Deborah A.; Lakew, Takele; Alemayehu, Wondu; Melese, Muluken; Zhaoxia Zhou; House, Jenafir I.; Hong, Kevin C.; Ray, Kathryn J.; Gandhi, Nandini; Whitcher, John P.; Gaynor, Bruce D.; Lietman, Thomas M. // Clinical Infectious Diseases;2/15/2008, Vol. 46 Issue 4, p564 

    The World Health Organization has distributed millions of doses of azithromycin to control the ocular chlamydial infection that causes trachoma. Theoretically, a loftier goal of elimination is feasible. Here, we demonstrate that, although local elimination of infection in the most severely...

  • Theoretical study of selective methylation in the synthesis of azithromycin. Duran, Dilek; Aviyente, Viktorya; Baysal, Canan // Journal of Computer-Aided Molecular Design;Jan2004, Vol. 18 Issue 1, p1 

    Azithromycin is a 15-membered macrolide antibiotic which is active in vitro against clinically important gram-negative bacteria. In this study, the selectivity of the methylation mechanism was analyzed computationally on the 2'-OCbz-3'-NMeCbz derivative of azithromycin in vacuum and in DME We...

  • Azithromycin-induced hiccups. Surendiran, A.; Krishna^Kumar, D.; Adithan, C. // Journal of Postgraduate Medicine;Oct-Dec2008, Vol. 54 Issue 4, p330 

    Hiccups are involuntary and rapid expulsion of air from the lungs with synchronous closure of glottis causing blockade of flow of air. This produces the characteristic hiccup sound. It is modulated by a reflex arc[1] with the afferents as phrenic nerve, vagus and sympathetic chain and the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics